Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTRA-V: U2-V vs U2 in CLL/SLL
NCT03801525Phase 3Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ublituximab, umbralisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by TG Therapeutics, Inc.. Started May 2019; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03801525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801525.